Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Open Access
- 1 October 2016
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (19), 4797-4806
- https://doi.org/10.1158/1078-0432.ccr-15-3153
Abstract
Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter. Experimental Design: Patients (n = 257) fulfilling eligibility criteria underwent central MGMT testing. Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg). Primary endpoint was overall survival at 12 months (OS12). A positive signal was considered >38 patients alive at 12 months in the per protocol population. A noncomparative reference arm of 54 patients evaluated the assumptions on OS12 in a standard-treated cohort of patients. Prespecified post hoc analyses of markers reflecting target activation were performed. Results: Both therapies were administered per protocol with a median of 13 cycles of maintenance temsirolimus. Median age was 55 and 58 years in the temsirolimus and standard arms, the WHO performance status 0 or 1 for most patients (95.5%). In the per protocol population, 38 of 54 patients treated with temsirolimus reached OS12. The actuarial 1-year survival was 72.2% [95% confidence interval (CI), 58.2–82.2] in the temozolomide arm and 69.6% (95% CI, 55.8–79.9) in the temsirolimus arm [hazard ratio (HR) 1.16; 95% CI, 0.77–1.76; P = 0.47]. In multivariable prognostic analyses of clinical and molecular factors, phosphorylation of mTORSer2448 in tumor tissue (HR 0.13; 95% CI, 0.04–0.47; P = 0.002), detected in 37.6%, was associated with benefit from temsirolimus. Conclusions: Temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter. Phosphorylation of mTORSer2448 in the pretreatment tumor tissue may define a subgroup benefitting from mTOR inhibition. Clin Cancer Res; 22(19); 4797–806. ©2016 AACR.Keywords
Other Versions
Funding Information
- Swiss National Science Foundation (FN31003A-138116)
- Swiss Cancer Ligue KFS (02670-08-2010)
This publication has 39 references indexed in Scilit:
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2009
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)Journal of Neuro-Oncology, 2008
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomasNeurology, 2006
- Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group StudyJournal of Clinical Oncology, 2005
- The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human GliomasJournal of Clinical Oncology, 2004
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−miceProceedings of the National Academy of Sciences of the United States of America, 2001
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProceedings of the National Academy of Sciences of the United States of America, 2001
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000